The pharmaceutical group Recordati Rare Diseases has appointed Milan Zdravkovic as its new Executive Vice President of Research and Development (R&D), reaffirming its commitment to innovation.
Extensive experience and track record
Zdravkovic, a Danish national, brings vast experience in creating innovative compounds and directing R&D organizations in the pharmaceutical industry.
His experience spans various therapeutic areas, from diabetes to infectious diseases, both common and rare. With 25 years in the sector, he has worked for companies such as Novo Nordisk, SOBI-Swedish Orphan Biovitrum and SNIPR Biome, holding key roles in R&D and medicine.
Words from Recordati's CEO
Recordati CEO Robert Koremans expressed his enthusiasm about Milan's arrival: "I am delighted to welcome Milan to the company. His extensive therapeutic knowledge, his experience in rare diseases and his leadership skills will be very valuable as we strengthen our R&D teams. He will play a fundamental role in the development of new medicines and in achieving our strategic objectives".
Milan Zdravkovic shares his vision
Milan Zdravkovic was also excited about joining Recordati: "Recordati has an impressive track record and solid knowledge of unmet patient needs. I am excited to be able to contribute to the company's 100-year legacy, and I feel very honored to lead innovation and development. I look forward to working with my colleagues to contribute to the future of the company".
Furthermore, Raffaele Sabia, who held a key role in Recordati's R&D and Medical Affairs function, has been appointed Medical Director. He will lead the Global Medical Office, which includes Medical Affairs, Health Economics and Outcomes Research, Patient Advocacy and Patient Safety.
He will also lead the Recordati Foundation for Rare Diseases, contributing to its mission of having a significant impact on healthcare and the community in general.
Information from: PMFarma.
Receive all industry news in our weekly Scientific Dialectics Newsletter.